[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355540-105":59,"doc-detail-355540-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","screening-of-kinase-inhibitors-in-the-triple-negative-kras-g13d-mutated-mda-mb-231-breast-cancer-cell-line","Screening of kinase inhibitors in the triple negative KRAS G13D-mutated MDA-MB-231 breast cancer cell line","","Triple negative breast cancer (TNBC) is often more chemoresistant and has worse prognosis, and a subset carries KRAS mutations such as KRAS G13D. A 157-compound kinase inhibitor library was screened in MDA-MB-231 cells to identify agents with strong antiproliferative and anti-migratory effects. Bosutinib and Dasatinib showed strong activity, while Saracatinib was less effective. RMC-7977 outperformed MRTX1133, and KRAS inhibitor combinations with Bosutinib, Dasatinib, and ERBB2 inhibitors enhanced effects, highlighting c-Abl as a relevant target and supporting combination strategies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/screening-of-kinase-inhibitors-in-the-triple-negative-kras-g13d-mutated-mda-mb-231-breast-cancer-cell-line/355540/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/screening-of-kinase-inhibitors-in-the-triple-negative-kras-g13d-mutated-mda-mb-231-breast-cancer-cell-line/355540.png","ImageObject",300,407,{"name":92,"@type":93},"Taylor Morgan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is KRAS G13D relevant in TNBC for this study?","Question",{"text":112,"@type":113},"A subset of TNBCs harbors KRAS mutations, and KRAS-driven invasion and progression depend on KRAS signaling. The study focuses on MDA-MB-231 cells carrying KRAS G13D to assess targeted vulnerabilities.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the kinase inhibitor library evaluated?",{"text":117,"@type":113},"A library of 157 kinase inhibitors was screened against MDA-MB-231 cells. Effective compounds were then assessed for synergistic antiproliferative effects in combination with KRAS inhibitors and for impacts on cell migration.",{"name":119,"@type":110,"acceptedAnswer":120},"Which inhibitors showed the strongest activity and what were the combination effects?",{"text":121,"@type":113},"Bosutinib and Dasatinib showed strong activity, while Saracatinib was less effective. Combining KRAS inhibitors with Bosutinib or Dasatinib, and to a lesser extent Saracatinib, along with ERBB2 inhibitors Neratinib and Mobocertinib, enhanced antiproliferative effects.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355540,1790816130,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099523885336,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nScreening of kinase inhibitors in the triple negative KRAS G13Dmutated MDA-MB-231 breast cancer cell line  \nSandra Stickler1, Marie-Therese Eggerstorfer1, Maximilian Rieche1, SinemArslan1,2, MaryanaTeufelsbauer3, Martin Hohenegger1, Lukas Weigl4 & Gerhard Hamilton1􀀍  \nTriple negative breast cancer (TNBC) is more chemoresistant and has a poorer prognosis than other breast cancer types. A subset ofTNBCs carries KRAS mutations or amplifications. MDA-MB-231 cells, which have a KRASG13D mutation and express HER2-103, were previously shown to be sensitive tothe KRAS G12D inhibitor MRTX1133 and ERBB2-targeting drugs. A kinase inhibitor library of 157 compounds was screened against MDA-MB-231 cells. Effective compounds and ERBB2-directed drugs were tested for synergistic antiproliferative effects in combination with two KRAS inhibitors and for their impact on cell migration. The BCR-ABL/SRC inhibitors Bosutinib and Dasatinib showed strong activity, while the SRC inhibitor Saracatinib was less effective. MDA-MB-231 lacks BCR-ABL but expresses c-Abl, as shown by Western blot and comparison with K562 cells. The tricomplex RAS(ON) inhibitor RMC-7977 was more effective than MRTX1133 . Combinations of KRAS inhibitors with Bosutinib, Dasatinib, Saracatinib (to a lesser extent), and ERBB2 inhibitors Neratinib and Mobocertinib enhanced antiproliferative effects. These findings highlight c-Abl as a relevant target in MDA-MB-231 TNBC cells. C-Abl and ERBB2 inhibitors can enhance the efficacy of KRAS-targeted therapies, offering potential combination strategies to overcome resistance in KRAS-positive TNBC.  \nKeywords Triple negative breast cancer, MRTX1133, RMC-7977, KRAS, c-Abl  \nA small subset of breast cancers, namely the approximately 10–15% of triple-negative breast cancers (TNBCs), is known to frequently harbor mutations of the KRAS (Kirsten rat sarcoma viral homolog) oncogene in conjunction with other drivers1,2. Metastatic progression in TNBC patients seems to be dependent on KRASsupported invasion3. TNBC is traditionally defined by the absence of the estrogen (ER) and progesterone (PR) receptors and absent or low expression of the human epidermal growth factor receptor 2 (ERBB2/HER2) and is characterized by its high metastatic potential and elevated risk of recurrence4,5. Conventional cytotoxic chemotherapy based on anthracyclines and taxanes is the traditional treatment option for TNBC6. Neoadjuvant chemotherapy achieves a pathological complete response (pCR) in approximately 30% of patients with TNBC7,8. In patients lacking a pCR, this chemotherapy spares a subpopulation of chemotherapy-resistant tumor cells leading to a poor outcome9. Alterations in TP53 were identified in 72/81 (89%) of TNBC cases and ERBB2 amplification was found in 7/81 (9%)10. Furthermore, loss of CDKN2A, CDKN2B and Ras/MAPK alterations could be detected with amplifications comprising PIK3CA (49%), KRAS (32%), BRAF (30%), and EGFR (23%)11. Recent advances have led to the identification of a HER2-low TNBC phenotype that responds to treatment with the antibody-drug conjugate (ADC) Trastuzumab deruxtecan (T-DXd)12, 13. Given the established role ofKRAS mutations in these tumors, the newly identified HER2 subtype offers novel treatment strategies14. Despite MDAMB 231 cells being characterized as HER2-negative, several research groups reported a low HER2 expression in this cell line15–17. This discrepancy seems to be linked to the alternative expression of HER2 by a unique circular HER2 RNA (circ-HER2) that encodes a novel HER2-103 protein, while regular HER2 mRNA and the corresponding protein can hardly be found18. Circ-HER2/HER2–103 was detected in approximately 30% TNBC  \n1Institute of Pharmacology, Medical University of Vienna, Waehringerstraße 13a, Vienna 1090, Austria.  \n2Department ofVeterinary Medicine and Animal Production, University of Naples Federico II,Via F. Delpino 1, Naples ","cbCaigVaHnFspmy7","https://ap.wps.com/l/cbCaigVaHnFspmy7","pdf",2884479,11,"English","# Screening of kinase inhibitors\n## Rationale and TNBC background\n## Experimental screening and combination testing\n## Key findings and therapeutic implications","[{\"question\":\"Why is KRAS G13D relevant in TNBC for this study?\",\"answer\":\"A subset of TNBCs harbors KRAS mutations, and KRAS-driven invasion and progression depend on KRAS signaling. The study focuses on MDA-MB-231 cells carrying KRAS G13D to assess targeted vulnerabilities.\"},{\"question\":\"How was the kinase inhibitor library evaluated?\",\"answer\":\"A library of 157 kinase inhibitors was screened against MDA-MB-231 cells. Effective compounds were then assessed for synergistic antiproliferative effects in combination with KRAS inhibitors and for impacts on cell migration.\"},{\"question\":\"Which inhibitors showed the strongest activity and what were the combination effects?\",\"answer\":\"Bosutinib and Dasatinib showed strong activity, while Saracatinib was less effective. Combining KRAS inhibitors with Bosutinib or Dasatinib, and to a lesser extent Saracatinib, along with ERBB2 inhibitors Neratinib and Mobocertinib, enhanced antiproliferative effects.\"}]","Screening of kinase inhibitors in the triple negative KRAS G13D-mutated MDA-MB-231 breast cancer cell line | PDF",1790119729,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/16556e4944b8603fbcf3f0b5343d8470.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8016381bfc8debfc98dae4192518dcae.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a8162c7cbd145d204a08ebdf1fc71147.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/92c9b9a0c5b65b99d2ad04754e6a1776.webp",980,1287]